Line V. Hansen

TL;DR: Recombinant human C4.4A, a structural homologue of the urokinase-type plasminogen activator receptor (uPAR), was originally identified as a metastasis-associated membrane protein, but little is known about its structural and functional properties, so a soluble truncated form of this protein is expressed, purified and characterized and used to produce specific polyclonal anti-C4.

TL;DR: The structural biology of uPAR will be reviewed with special emphasis on its multidomain composition and the interaction with its natural protein ligands, i.e. the serine protease uPA and the matrix protein vitronectin.

TL;DR: High tumour cell C4.4A expression is associated with shorter survival for NSCLC patients and this correlates with overall survival, and multivariate Cox regression analysis shows this protein is an independent predictor of poor disease outcome inNSCLC.

TL;DR: A soluble truncated form of the third domain of the urokinase receptor is used as a convenient C-terminal fusion partner for various recombinant extracellular human proteins used in basic cancer research.

TL;DR: C4.4A is expressed during invasion and metastasis of human ESCC and may thus provide a new histological marker in this disease, and is analyzed in 14 esophageal squamous cell carcinomas.